Recently, National Cancer Institute has reported a novel inhibitor TAK-981 for SUMOylation enzymatic cascade. This inhibitor showed potential immune-activating and antineoplastic activities. Firstly, TAK-981 targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, forming an adduct with SUMO. This binding blocks the transfer of...